About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Jul 03, 2013... Israel has provided the global drug development pipeline with many well–known internationally successful medications including Copaxone, Rebif, Exelon, Doxil, Azilect and Gonal. In fact there is yet another well–known drug that is not very often associated with Israel – Enbrel, for the treatment of inflammatory diseases and probably the most successful Israeli drug that you do not recognize as Israeli.
Oct 11, 2011...
October is National Breast Cancer Awareness Month
October is National Breast Cancer Awareness Month, bringing critical attention to what is today the most common form of cancer in women, apart from skin cancers. Most breast cancers begin in the cells that line the milk ducts (ductal carcinoma) or in the milk-producing glands (lobular carcinoma). At the Weizmann Institute of Science, researchers are studying genes and hormones that play a role in these cancers and are developing better diagnostic tools and treatments. Some examples of this research are presented below.
https://weizmann-usa.org/news-media/feature-stories/november-is-american-diabetes-month/
Nov 01, 2017... As we enter a time of year abundant with food-centric holidays and gatherings, it can be helpful to pause for a moment to think about how we eat – and how much. We all know that overeating and consuming unhealthy foods often leads to obesity, which often leads to diabetes – frequently as part of metabolic syndrome, a cluster of conditions comprised of four interrelated illnesses: obesity, diabetes, heart disease, and high blood pressure. But despite this awareness, diabetes rates keep soaring worldwide. In the U.S. alone, reports the American Diabetes Association, more than 29 million of us have the disease – that’s 1 in 11 people. Even more alarming is that 86 million Americans have prediabetes, meaning that 1 in 3 are on the verge of becoming diabetic.
https://weizmann-usa.org/news-media/in-the-news/my-intuition-says-teva-will-get-out-of-this/
Oct 09, 2017...
Prof. Michael Sela Photo: Eyal Izhar
“My intuition tells me that Teva will extricate itself,” Professor Michael Sela, who, together with Ruth Arnon and Deborah Teitelbaum, developed Teva’s blockbuster multiple sclerosis treatment Copaxone at the Weizmann Institute, told “Globes” yesterday.
It was Sela’s close friendship with the late Eli Hurvitz, Teva’s legendary CEO, that brought Copaxone to Teva and made the company what it is today. Former Teva CFO, and currently a director of the company, Dan Suesskind has related in the past how Sela spoke to Hurvitz about a potential drug, COP-1, which eventually became Copaxone. “Fortunately, Teva was allowed to look at the drug file for just $50,000. Who knows, maybe if thrifty Eli had been offered the file for $500,000, Copaxone would never have seen the light of day,” Suesskind said.
https://weizmann-usa.org/news-media/video-gallery/best-people-best-science/
Jul 06, 2016... The Weizmann Institute's most important asset is its people. That's why the Institute is committed to recruiting and nurturing some of the world's brightest young researchers. Here, six impressive new scientists – Drs. Ronen Eldan, Ofer Firstenberg, Yifat Merbl, Neta Regev-Rudzki, Nir London, and Efi Efrati – share how the Institute is helping them make breakthroughs in areas ranging from malaria to optics.
https://weizmann-usa.org/news-media/in-the-news/bacteria-alert-by-scientist/
Dec 01, 2017...
The Israeli crystallographer, who shared the chemistry Nobel with Venkatraman Ramakrishnan and Thomas A. Steitz in 2009 for her work on ribosome, was delivering the 79th Foundation Day lecture on “Next Generation Environmental Friendly Antibiotics” at Bose Institute on Thursday.
“Resistance to antibiotics is a real big problem to modern medicine. Multi-drug resistance has developed not because we use antibiotics, but because bacteria has evolved and uses mechanisms against other bacteria in their fight for resources,” Yonath said.
Dec 20, 2011...
Teva Pharmaceutical Industries Ltd., the world’s largest generic-drug maker, is seeking to transform a compound once rejected by Sanofi into the first treatment to succeed insulin for Type 1 diabetes.
The therapy, DiaPep277, is made from a human protein that stops the immune system from destroying the pancreatic beta cells that secrete insulin, a hormone needed to convert sugar, starches and other food into energy. The drug also helps control sugar levels in the blood, a late-stage study showed last month.
Mar 20, 2019...
Yeda CEO Gil Granot-Mayer (left to right) BioLeaders CEO, Dr. Young-Chul Park and Weizmann Institute Vice President for Technology Transfer Prof. Mordechai Sheves (Weizmann Institute of Science)
An anti-cancer therapy that has been developed by scientists at the Weizmann Institute of Technology will get a $10 million investment from a South Korean biopharmaceutical company that is traded on the Korea Stock Exchange. This is the Korean firm’s first investment in an Israeli venture, the Weizmann Institute said in a statement.
Oct 11, 2011...
“I believe there is real magic in the way thatembryos develop. I’ve been studying them for almost 15 years and Ihaven’t stopped being amazed,” says Dr. Karina Yaniv of the WeizmannInstitute of Science’s Department of Biological Regulation.
Dr. Yaniv focuses on examining how blood and lymphatic vessels formduring embryonic development. Her research may, in the future, lead tonew therapies for heart disease, stroke, cancer, and other illnesses. “Ithink it’s imperative for us to learn how to manipulate vessel growth,”she says. “Sometimes we want to encourage vessel growth and sometimeswe want to stop it.”
Jun 06, 2016...
Dr. Bruce Lasker of Pfizer and Dr. Berta Strulovici, head of the G-INCPM, on the Weizmann campus
REHOVOT, ISRAEL—June 6, 2016—The Weizmann Institute of Science in Rehovot, Israel, and Yeda Research and Development Co., Ltd., its commercial arm, announced this week that they have entered a multi-year arrangement with Pfizer Inc. The arrangement will entail collaboration at the newly established National Drug Discovery Institute (DDI) in the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), which is part of the Weizmann Institute and located on its campus. Pfizer will be supporting the G-INCPM by placing a Pfizer medicinal chemist (rotating on a yearly basis) at the Institute to assist with advancing target selection and high-throughput screening, as well as leading development campaigns for programs that enter the DDI. If projects of mutual interest – those that hold promise in addressing unmet medical needs – are identified, Pfizer and Yeda will evaluate the potential for research and development agreements.
©2023 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR
